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Abstract
Background: Adaptive designs have been increasingly used in the pharmaceutical and device industries, but adoption
within the academic setting has been less widespread — particularly for confirmatory phase trials. We sought to
understand perceptions about understanding, acceptability, and scientific validity of adaptive clinical trials (ACTs).
Methods: We used a convergent mixed methods design using survey and mini-focus group data collection
procedures to elucidate attitudes and opinions among “trial community” stakeholders regarding understanding,
acceptability, efficiency, scientific validity, and speed of discovery with adaptive designs. Data were collected about
various aspects of ACTs using self-administered surveys (paper or Web-based) with visual analog scales (VASs) with free
text responses and with mini-focus groups of key stakeholders. Participants were recruited as part of an ongoing NIH/
FDA-funded research project exploring the incorporation of ACTs into an existing NIH network that focuses on
confirmatory phase clinical trials in neurological emergencies. “Trial community” representatives, namely, clinical
investigators, biostatisticians, NIH officials, and FDA scientists involved in the planning of four clinical trials, were eligible
to participate. In addition, recent and current members of a clinical trial-oriented NIH study section were also eligible.
Results: A total of 76 stakeholders completed the survey (out of 91 who were offered it, response rate 84 %). While the
VAS attitudinal data showed substantial variability across respondents about acceptability and understanding of ACTs
by various constituencies, respondents perceived clinicians to be less likely to understand ACTs and that ACTs probably
would increase the efficiency of discovery. Textual and focus group responses emerged into several themes that
enhanced understanding of VAS attitudinal data including the following: acceptability of adaptive designs depends on
constituency and situation; there is variable understanding of ACTs (limited among clinicians, perceived to be higher at
FDA); views about the potential for efficiency depend on the situation and implementation. Participants also frequently
mentioned a need for greater education within the academic community. Finally, the empiric, non-quantitative
selection of treatments for phase III trials based on limited phase II trials was highlighted as an opportunity for
improvement and a potential explanation for the high number of neutral confirmatory trials.
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Conclusions: These data show considerable variations in attitudes and beliefs about ACTs among trial community
representatives. For adaptive trials to be fully considered when appropriate and for the research enterprise to realize the
full potential of adaptive designs will likely require extensive experience and trust building within the trial community.
Keywords: Adaptive clinical trials, Mixed methods research, Bayesian statistics, Emergency medicine, Neurology,
Clinical trials
Background
Randomized controlled trials represent the gold standard
for discovering new treatments for disease. Clinical trial
designs have evolved over time, yet innovations in design
have not commonly been observed in large-scale con-
firmatory trials. Recently, the National Institutes of
Health (NIH) and the Food and Drug Administration
(FDA) have taken interest in the potential of adaptive
designs for accelerating the bench-to-bedside transition
of new scientific breakthroughs [1].
Adaptive clinical trial (ACT) designs use accumulating
data on patients from within a trial to make decisions
about the future conduct of a trial [2, 3]. Adaptations
can include comparisons of multiple dose tiers, response
adaptive randomization (i.e., more subjects randomized
to dose tiers with a greater probability of effect or a
lower probability of toxicity), sample size re-estimation,
and efficacy/futility stopping rules. In order to be able to
define type I error rates, all potential changes to the trial
must be pre-specified [4, 5]. Adaptive designs have been
increasingly used in the pharmaceutical and device in-
dustries, but adoption within the academic setting has
been less widespread — particularly for confirmatory
phase trials [6–8].
As an emerging form of clinical trial with some fea-
tures that seemingly contradict some perceptions about
“traditional, fixed clinical trials,” ACTs may be perceived
as a threat to the status quo [9]. Particularly in the age
of team science, success of the research enterprise is
dependent upon collaboration and communication
against multiple constituencies [10]. An understanding
of the opinions of the “trial community,” namely, clinical
investigators, biostatisticians, NIH officials, FDA scien-
tists, and study section members, could help define
current attitudes and beliefs about adaptive designs and
ACTs. These multiple constituencies are all key stake-
holders in the clinical trial enterprise, and a better un-
derstanding of their attitudes and beliefs about
acceptability and understanding of ACTs, efficiency, sci-
entific validity, and speed of discovery could provide a
window on the perceived place of ACTs in contemporary
clinical science.
Currently, relatively little published data exists regarding
the opinions of the academic trial community, particularly
with respect to ACT use for confirmatory phase trials.
Surveys of industry trial stakeholders, mostly from
pharmaceutical developers in 2008 and 2012, found that
managing the changes during trial operation was the lar-
gest barrier; education and time/resources for planning
were minor concerns [11, 12]. Given this gap in the litera-
ture, here we aimed to describe the views of constituencies
from academia and government participating in the Adap-
tive Designs Accelerating Trials into Treatments
(ADAPT-IT) project, and compare their beliefs about un-
derstanding and acceptability of adaptive designs, and




We conducted a convergent mixed methods design that
used a 22-item ACT beliefs survey with categorized vis-
ual analog scales (VASs), free text survey responses, and
mini-focus groups, a type of group interview that focuses
on three or four respondents and helps facilitate the par-
ticipation of all in the discussion versus a larger conven-
tional focus group [13, 14]. Additionally, the mini-focus
groups were employed to maintain homogeneity among
the types of stakeholders (having the academic biostatis-
ticians together) and to enhance the interactivity of the
groups. A mixed methods approach was implemented to
elucidate participants’ beliefs, to identify the reasoning
behind the beliefs expressed, and to integrate the data to
provide the broadest possible understanding. Study in-
struments were developed by experts in both traditional
and adaptive clinical trials (WJM, RL) and a mixed
methodologist and ethicist (MF) and focused on partici-
pants’ beliefs about ACT designs. The ADAPT-IT mixed
methods evaluation team previously reported on the
opinions regarding the ethics of ACT designs from data
from a subset of respondents in the current report [15].
In addition, we published perspectives and lessons
learned from the overall trial planning process employed
by ADAPT-IT [16]. We structured our study design and
reporting in accordance with the consolidated criteria
for reporting qualitative research (COREQ) statement
(see Additional file 1) [17].
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Settings and participants
Participants were recruited as part of an ongoing NIH/
FDA-funded research project exploring the incorpor-
ation of ACT designs into an existing Neurological
Emergencies Treatment Trials (NETT) Network [1, 18].
So far, one of the trials planned in ADAPT-IT has been
fully planned, funded, and is enrolling patients, and
there is another prospective comparison of a pre-
specified adaptive design to an ongoing clinical trial that
was developed; the other projects are still being devel-
oped [19, 20]. Clinicians, preclinical scientists, and bio-
statisticians who were planning clinical trials were
initially recruited as part of the grant proposal for
ADAPT-IT; after it was funded, all were invited to the
trial planning meetings and survey. We intentionally
sampled for key trial leaders for the mini-focus groups.
Project investigators held a series of meetings that in-
cluded experts in ACT design and investigators inter-
ested in developing an ACT for specific research topics
related to neurological emergencies. A mixed methods
team assessed the ACT development process during
these meetings and conducted the analysis. Since several
trials were developed over time with different teams, re-
sponses in the current investigation are from baseline
surveys or mini-focus groups that occurred prior to any
ADAPT-IT trial planning activities.
Data collection
Data were collected with self-administered surveys, ei-
ther by paper or on the Web, by using VAS and free text
responses. The survey was revised after an initial pilot
phase where it was administered to clinician researchers
experienced in clinical trials and survey administration,
but who were not otherwise involved in the project. Data
also were collected during five mini-focus groups with
four to six clinical trial experts per group [13, 14].
ADAPT-IT participants from clinical medicine and bio-
statistics who were present for trial planning meetings
were recruited for the mini-focus groups. The mini-
focus group guide was specifically designed with topics
to parallel the items on the VAS instrument so that re-
sults from both instruments could be mapped together.
Data were collected between January and August of
2011. Participants were classified as belonging to one of
the following groups of clinical trial experts: academic
biostatisticians from NIH-funded clinical trial networks
(n = 5) with substantial experience running phase III tri-
als, consultant biostatisticians working in academic or
industry settings with specific experience in Bayesian
adaptive designs (n = 6), academic clinician researchers
(n = 22), and other stakeholders, e.g., NIH officials, FDA
statisticians, medical officers, and patient advocates —
all experts in the planning of clinical trials (n = 20).
Recent and current members of a clinical trial oriented
NIH study section (grant review panel) were also eligible
(n = 23). No patients were surveyed for this report. In-
stead we asked those surveyed for their opinions about
how patients might view the advantages and disadvan-
tages of ACTs. These individuals were offered an an-
onymous Web-based version of the VAS survey. The
survey questions were piloted and revised for clarity and
purpose on clinical trial experts not otherwise involved
in ADAPT-IT. We used the paper survey only at the first
in-person trial planning meeting, and we transitioned to
an identical, Web-based version for all subsequent data
collection. The VAS survey and discussion guide are
available at the following links from our previous publi-







Survey and mini-focus group questions were formulated
to gather opinions of the clinical trial experts regarding
scientific, logistical, and other advantages and disadvan-
tages of ACT designs. Participants considered advan-
tages and disadvantages from the perspectives of the
patient, the researcher, and society as a whole.
Data sources
Mini-focus groups with clinical trial experts were
conducted before the initial face-to-face scientific
planning meetings for four of the five trials [13, 14].
These mini-focus group sessions were digitally re-
corded (audio only) and transcribed verbatim, and the
data were entered into Atlas.ti v6.0 for data manage-
ment, coding, and analysis [21].
Participants answered the VAS items by completing a
paper survey or a Web-based survey. The VAS allowed
participants to mark a point of agreement on a con-
tinuum ranging from “definitely not,” to “probably not,”
to “possibly,” to “probably,” to “definitely.” We used a
100-point scale to allow more resolution to examine dif-
ferences than a 5-point structured Likert scale would
allow, as we desired respondents to make estimations on
a probability scale. To compute a quantitative measure
of a participant’s assessment, we assigned the lowest an-
chor a value of 0 and the highest anchor a value of 100
and calculated a level of agreement score based on the
point chosen by the participants for the VAS items. The
Web-based survey provided a number, so it was clear to
respondents that the entire scale could be used.
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Data analysis
Descriptive statistics (proportions and means) were cal-
culated for demographic variables. The VAS data were
depicted by using box plots visually illustrating the
median, interquartile range (IQR), and outliers (outside
1.5 times the IQR) for each survey question. Regarding
the qualitative analysis, open coding was conducted ini-
tially, then reviewed together to develop a coding
scheme; this was then used independently for several
transcripts to refine interpretation of the codes. The five
mini-focus groups and free text responses from the sur-
veys were analyzed independently by two investigators
(LL, SMF) from the mixed methods evaluation team
with an 88 % intercoder agreement [22]. The develop-
ment of a coding scheme was based initially on the the-
matic basis of the interview guide and revised to reflect
the primary themes that emerged from the analysis. The
VAS scores using box plot diagrams were integrated
with comments by constituency groups for subanalyses
to merge quantitative ratings with qualitative textual
data and with representative quotations [23]. The attitu-
dinal data from the VASs were organized to facilitate
comparisons by the respondent constituencies, and key
domains, understanding and acceptability of ACTs, effi-
ciency, scientific validity, and speed of discovery.
We used the qualitative analytic procedures of
immersion (researchers immersing themselves in the
data) and crystallization (researchers reflecting on how
ideas about what meanings in the data crystallize out as
major findings). The coding scheme evolved to have
seven major domains: ACTs-General Issues (four sub-
themes), Logistics (three subthemes), Ethics (four sub-
themes), Regulatory Issues (two subthemes), NIH (three
subthemes), Journals (two subthemes), and Translation
(two subthemes). After coding the data, text searches
were conducted to bring together similar content and
allow integration of the data through merging, a key
methodological approach to integration in mixed
methods study [23]. Qualitative quotations were used to
illustrate and expand understanding of the diverse,
sometimes concordant, and sometimes conflicting views.
The instruments are fully described and available for
download in our previous report limited to the ethical




The survey was offered to 64 participants in the
ADAPT-IT project, of whom 53 responded; in addition
the survey was offered to 27 members of an NIH study
section, of whom 23 responded (overall response rate
84 %). Overall, the median age was 49 years, the sample
was split closely evenly between PhDs and MDs, and
more than a third were women (Table 1).
Overarching views about understanding and acceptability
of ACTs in the trial community
Respondents assessed understanding and acceptability of
adaptive designs from the perspective of five major con-
stituencies: the FDA, NIH review panels, researchers, cli-
nicians, and journal peer reviewers. The overarching
opinions are provided in Fig. 1. From the VAS data over-
all, the respondents were generally positive towards
adaptive designs. Specifically, it appears that the respon-
dents as a group felt that the FDA was most likely to
understand adaptive designs and that clinicians were
least likely to understand these designs.
From the focus group transcripts, we identified
specific responses that seemed to exemplify the VAS
findings. One clinician trialist’s general view about the
entire funding implementation and publishing enterprise
was that clinicians would accept adaptive design studies
which were published in major peer-reviewed journals.
However, she thought it unlikely that clinicians would
understand them. In her opinion, review was a matter of
Table 1 Characteristics of participants, n = 75. IQR represents
range between 25th and 75th percentiles
Characteristic Median IQR
Age 49 44-56
Female, n, percentage 27 37 %
Highest degree
MD or equivalent 43 57 %
PhD 32 43 %
Primary work location
University/university hospital 47 64 %
Community hospital 5 7 %
Government (NIH or FDA) 15 21 %
Consulting firm 5 7 %
Other 2 3 %
Primary specialty (if physician)
Neurology 23 55 %
Emergency medicine 9 21 %
Internal medicine 3 7 %
Other 7 17 %
Primary professional activity
Clinical practice 10 13 %
Research 22 29 %
Teaching 6 8 %
Administration 13 17 %
Statistical 9 12 %
Government 17 22 %
Meurer et al. Trials  (2016) 17:373 Page 4 of 13
luck. At study section the study is flagged as an adaptive
design, and the “SRA (scientific review administrator)
would find someone with expertise to review it.” This
guaranteed “the reviewing statistician would understand
the protocol, even if they did not like it.” For a journal,
she felt that review was much more a “roll of the dice.”
To better understand how views of the clinical trial
community vary by constituency and specific issues, we
further examined respondents’ views more closely, con-
stituent by constituent, as illustrated below.
Understanding of adaptive designs by NIH review panels
The respondents generally had neutral to mildly positive
attitudes regarding the extent to which NIH review
panels would understand and accept adaptive design
proposals (Fig. 2). Among all groups, the academic and
study section biostatistician respondents had noticeably
less optimistic views regarding the understanding of
phase III adaptive trials by NIH study sections, particu-
larly relative to phase II proposals. Widely dispersed
VAS responses by these groups indicate varied opinions
within this group with strongly polarized feelings that
NIH peer review panels will accept or not accept phase
III adaptive designs as valid. For example, a consultant
statistician noted that many reviewers may not have
been trained in or familiar with adaptive design
methods. A clinician trialist echoed the belief that
statisticians at the NIH review (committee) and clinical
researchers who believe they understand statistical de-
sign on the NIH review (committee) will probably not
understand the adaptive design and how it is applied to
the phase II study.
Regarding process, a clinician trialist opined that the
statisticians would become the default authority at study
section. The trialist expressed the notion that statisti-
cians on the panels would understand the adaptive
design, while clinicians would not. Rather, the clinicians
would ask the statisticians for their opinion and defer to
their views. Others noted that even among statisticians
there is a large range of experience and that there is lim-
ited coverage of adaptive designs and clinical trial simu-
lation within most PhD biostatistics curricula. Pessimism
about the ability to find qualified reviewers reinforced
concern about ACTs getting a fair review. Respondents
worry that NIH review panels may not have biostatisti-
cians with experience in more complex adaptive designs.
They also cite the short page limits and the challenge
study sections have to understand the complex designs,
given a reduced ability to reproduce the sample size esti-
mations (whereas more fixed designs using standard fre-
quentist t tests or differences in proportions are easy to
replicate quickly). One clinician trialist summarized a
common sentiment that the statistical expertise did not
currently exist on NIH review to completely understand
Fig. 1 Distribution of attitudes about 15 aspects of ACTs for all respondents combined. Center lines represent median, boxes represent 25th and
75th percentiles, and whiskers represent the highest and lowest observed values that fall within 1.5 times the interquartile range
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the adaptive design process, except in concept. Their
hope was that the NIH would be willing to allow adap-
tive design studies to move forward if developed by well-
recognized experts.
Acceptance of adaptive designs by NIH review panels
To compare with questioning about understanding, we
also solicited opinions about the respondents’ percep-
tions of NIH review panel acceptance of adaptive de-
signs. As with understanding, respondent opinions
ranged from pessimistic to very optimistic regarding ac-
ceptance (Fig. 2). A consultant statistician optimistically
stated that “forms of these designs have been used for
many years” and, in their opinion, the designs were
“demanded” by the NIH. In contrast, an academic bio-
statistician felt that NIH panels may be more likely to
accept adaptive designs even if they do not necessarily
understand them, mainly because they are considered to
be innovative and provide other efficiencies. In the mid-
dle ground, a study section biostatistician felt that ac-
ceptance would depend on the situation and only after
consideration of whether an adaptive design would
confer an advantage. It was this biostatistician’s opinion
that not all adaptations are the same, and some ap-
proaches may be valid for early phase trials but not for
confirmatory trials. The idea of adaptation seems at odds
with the notion of a “confirmatory” clinical trial, except
for narrowly defined adaptations, e.g., blinded sample
size re-estimation. For this reason, adaptive designs are
valid, but not always better than traditional approaches.
In the opinion of this biostatistician, like traditional
trials, adaptive design trials need to be properly de-
signed, executed, and analyzed.
Many respondents felt that even if there were inad-
equate understanding of adaptive designs, there would
still be enthusiasm based on the novelty of designs.
For example, an academic biostatistician expressed the
belief that reviewers may be more likely to accept
phase II designs as valid (over phase III) because they
were not confirmatory trials. Further, the biostatisti-
cian thought that some reviewers may accept adaptive
designs as valid, even if they did not completely
understand the methodology. A clinician trialist felt
that many clinicians will accept what statisticians tell
them are valid designs. Another clinician trialist sum-
marized his thoughts about understanding and accept-
ance, saying that while many clinicians will not
understand these designs, the clinical trials study sec-
tion (at least at the National Institute of Neurological
Disorders and Stroke, NINDS) had statisticians who
are very capable of understanding adaptive design tri-
als, whether or not they accepted them as the best way
to conduct a trial. The clinician felt that this was the
same case for the FDA. Another participant expressed
trepidation of the “safety” of submitting an adaptive
design, and concerns that adaptive designs would not
be submitted to the FDA. In their opinion, investiga-
tors in need of funding would hesitate to submit
adaptive design analysis that might be perceived as
too novel. Therefore, it was safer to design trials
using standard statistical methods, even if they were
not optimal.
Fig. 2 Perceived understanding and acceptance of adaptive designs by FDA and NIH. Center lines represent median, boxes represent 25th and
75th percentiles, and whiskers represent the highest and lowest observed values that fall within 1.5 times the interquartile range
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Understanding and acceptance: opinions regarding FDA
review
While opinions varied greatly, in general the participants
perceived that the FDA would have the greatest under-
standing of adaptive designs. As illustrated in Fig. 1,
respondents generally rated the FDA as having a high like-
lihood of understanding ACTs. Interestingly, the same re-
spondents overall were not as convinced that better
understanding translates into acceptance of ACTs. This
did not seem to vary significantly by constituency affili-
ation (Fig. 2), although academic biostatisticians appeared
to have more neutral views regarding FDA understanding.
Understanding of adaptive designs by the FDA
Generally, participants believed that the FDA under-
stands adaptive designs, since the FDA has issued guid-
ance documents on adaptive design clinical trials.
However, others believed there is more heterogeneity of
understanding within the FDA. One academic biostatis-
tician felt that the degree of understanding depended on
the branch of the FDA and the specific group of statisti-
cians. The reason for the faith in understanding by the
FDA aligned with the perception that the FDA has the
most previous experience with ACTs. An FDA scientist
pointed out that the FDA has accepted well-understood
adaptations for years, but some more difficult adaptive
designs may be better understood than others.
Acceptance of adaptive designs by the FDA
Respondents also expressed some doubt as to whether
the FDA’s better understanding of complicated adaptive
designs would translate into the FDA accepting the re-
sults due to perceived problems with broader interpret-
ability. According to a clinician trialist, the FDA would
not accept any type of analysis that could leave open the
possibility that the result occurred because of chance or
unforeseen circumstances. This trialist felt that the FDA
desires simple designs so that they can unequivocally
support the primary outcome measure and so that prac-
titioners can easily understand the results. Therefore,
the FDA may understand the designs but may not accept
the results as valid. This opinion contrasts with that of
other respondents who more optimistically pointed out
that the FDA has a major push towards improving the
efficiency of the medical device approval process and
that adaptive designs are to be a part of that. A consult-
ant biostatistician noted the FDA’s history of acceptance
of new methods, pointing out that the Critical Path
Initiative encouraged the FDA to accept well-designed
adaptive trials. In further contrast, others felt that under
a broad definition of “adaptations,” most currently con-
ducted trials are adaptive and are generally accepted as
such. An academic biostatistician explained that:
The NIH and FDA already accept adaptive designs
based on pre-specified blinded analysis of interim
results, as well as pre-specified group sequential de-
signs. Other researchers have considered adaptive
modification of randomization ratios across treat-
ment arms or within strata defined by eligibility
criteria. (Such can in some sense be viewed as in-
cluding adaptive dropping of treatment arms or
subgroups.) In my experience, the FDA has already
accepted adaptive selection of subgroups and doses
based on interim estimates of treatment effects
when those rules were pre-specified in an easily
understood manner.
Clinicians expressed a need for the adaptive design to
justify itself to the FDA (and NIH). A clinician trialist
felt that a study would have “to be improved by an adap-
tive design, either by making it cheaper or easier to in-
terpret, in order for NIH or FDA to prefer that design
over the frequentist approach.”
Understanding and acceptance: respondent opinions
regarding the clinical and research community
Adaptive designs were felt to be understood variably
across the constituencies of researchers, clinicians,
and journal peer reviewers (Fig. 3). Moreover, respon-
dents generally believe that clinicians and clinician re-
searchers have limited understanding of ACTs. The
sources of the diverse views about the ability to
understand and to accept adaptive designs are
expressed through the qualitatively collected com-
ments. In contrast to the extensive experience in the
private world, some respondents noted the impact of
limited experience in the academic setting as an im-
pediment to understanding adaptive designs. An
academic biostatistician noted that although adaptive
design trials are becoming more common, several
researchers, particularly in the academic setting, have
little experience designing and conducting phase II
adaptive designs. More experience would allow for
better understanding of these designs. The respon-
dents expressed concern that when research results
are published, the broader medical community would
have very little understanding of the actual design. A
patient advocate felt that researchers and peer re-
viewers would not understand or accept what has
been provided, unless there was legitimate and applic-
able proof. Further, they felt that clinicians were more
apt to understand and accept new clinical trial design
approaches. In addition, a FDA scientist expressed the
concern that clinicians would not understand the re-
sults from ACTs and felt this was an important area
that needed more discussion.
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Understanding and acceptance: opinions regarding the
statistical community
While the respondents were not asked to specifically
opine regarding statistician attitudes towards adaptive
designs in the VAS instruments, focus group discussions
often involved opinions regarding how statisticians from
various venues including the FDA, academia, and indus-
try would be expected to respond to adaptive designs.
Opinions regarding statistical experience mirrored what
was thought of the broader academic research commu-
nity in clinical trials: Understanding is highly variable,
and the majority of statisticians in academic practice
have limited experience with more complex adaptive de-
signs. Respondents pointed out that statisticians have
variable experience with these designs, ranging from
nearly no experience to the design of hundreds of adap-
tive trials. Other barriers that the biostatistician men-
tioned were the lack of print exposure and training,
noting that often statisticians are not given much room
to describe the design in detail in a clinical journal. Pre-
conceived biases on the part of statistical reviewers were
an additional hindrance.
The respondents also noted that clinical researchers
generally expect all statisticians to be experts in all types
of clinical trial designs, despite the large range of experi-
ence observed among statisticians and the limited cover-
age of adaptive designs and clinical trial simulation within
most PhD biostatistics curricula. Another view among
some respondents is that varied understanding among dif-
ferent constituencies should be expected, but that designs
should not circumvent good science. An academic
biostatistician noted that generally the important operat-
ing characteristics between adaptive and non-adaptive de-
signs are not radically different. This biostatistician also
stated that strong advocates of adaptive design trials
should emphasize the ways that adaptive designs could be
used to strengthen the scientific method.
Opinions regarding efficiency, validity, and potential to
speed discovery
In addition to the comparisons of respondents’ views
about understanding and acceptability in the research
community, we also examined the domains of efficiency,
scientific validity, and speed of discovery. Figures 1 and
4 illustrate respondents’ attitudes about efficiency, scien-
tific validity, and speed of discovery. In general, the re-
spondents were optimistic about the potential for ACTs
on these subjects, particularly on the efficiency domain.
In addition, academic biostatisticians provided responses
in the neutral range on these three domains. The textual
responses below illustrate some important nuances to
this optimism.
Efficiency may be increased, decreased, or unchanged by
adaptive designs depending on the planning and
implementation
The respondents provided several views on efficiency from
the mini-focus groups. One example is that it seems that
clinicians/non-statistician researchers generally believe
that adaptive designs can simply reduce the overall sample
size. This efficiency was an advantage that would offset
the perception that the analysis or adaptive designs were
Fig. 3 Perceived understandibility and acceptability of adaptive designs by researchers, clinicians, and journal peer reviewers. Center lines represent
median, boxes represent 25th and 75th percentiles, and whiskers represent the highest and lowest observed values that fall within 1.5 times the
interquartile range. Variability perceived by clinicians and study section clinicians. (Consultants have journal peer reviewer bad experiences.)
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convoluted and hard to follow. An academic biostatisti-
cian pointed out that adaptive designs may or may not re-
duce the sample size, but they will generally change the
number of scientific questions that can be answered quan-
titatively and offer other advantages. The sample size was
dependent on the phase of the trial, what was being
adapted, and how the researchers defined efficiency. In
the opinion of an academic biostatistician, a comparison
of a trial completed under different designs was needed to
answer the question of what advantages adaptive design
trials conferred.
In another twist, some have strong opinions regarding
the potential for increased efficiency. A consultant bio-
statistician stated that adaptive design trials are more ef-
ficient in terms of patients and resources, saying that
there could be huge savings in running a clinical trial.
They further opined that the “non-adaptive” approach
was leading the USA into bankruptcy due to health care
costs. A consultant biostatistician expanded further:
Efficiency may be conceptualized either as identifying
effective treatments from a large pool of candidates or
as minimizing the “cost” of answering a discrete
clinical question. The opportunity cost of conducting
any trial (in terms of not being able to dedicate
resources to answering other questions or exploring
other treatments) is not frequently a design or review
consideration. While adaptive designs may improve
the efficiency of finding treatments from a pool of
candidates, the benefits within a single constrained
question may be more limited.
An academic biostatistician pointed out that adaptive
trials could increase the number of questions at each
stage of a trial “at the price of having less information
with which to address some of these questions.” One
academic biostatistician lamented that some adaptive de-
signs tended to decrease the overall efficiency of re-
search due to the lack of attention to the adaptive rules
that had been chosen.
A clinician trialist pointed out that adaptive designs
produce valid results; however, if primary outcomes are
different enough, researchers may lose the power with
which to study secondary outcomes (for example, if too
few patients are assigned to an arm that “loses” on pri-
mary outcome). This could be detrimental, since there
are times when the secondary outcomes are also import-
ant. In an example trial, two antiepileptic drugs (AEDs)
were compared head to head. The clinician trialist de-
scribes this scenario in further detail: “Drug A is found
to be more effective but patients develop many more
cognitive side effects. In a traditional trial design Drug A
‘wins’ on primary outcome (efficacy) and ‘loses’ on sec-
ondary. In an adaptive design Drug A would win on
Fig. 4 Perceived efficiency and scientific validity of adaptive designs. Center lines represent median, boxes represent 25th and 75th percentiles, and
whiskers represent the highest and lowest observed values that fall within 1.5 times the interquartile range
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cognitive function but may have insufficient power to
determine whether secondary outcomes were signifi-
cantly worse.”
The validity of inference derived from more complicated
ACTs is an area of varied opinions
Most groups indicated overall optimism regarding validity;
however, the academic biostatisticians appear to have a
more neutral view (Fig. 4). The textual responses show
that clinicians and non-statistician researchers may not be
able to assess the validity of ACT designs and will gener-
ally defer to their known biostatistician collaborators, who
may or may not actually have experience with the designs
in question. An academic biostatistician explained that in
his experience clinicians embraced adaptive designs; how-
ever, they were in danger of accepting their validity with-
out understanding the statistical details. According to an
academic biostatistician, the key to the scientific method
is the isolation of questions that an experiment is designed
to answer. They feared adaptive designs can be used im-
properly, blurring the definition of the scientific hypoth-
esis that is answered. Therefore, proper interpretation of
the results must guard against the possible bias of investi-
gators in reporting results that may diminish the true
gains that are possible with a systematic adaptive ap-
proach to addressing many alternative hypotheses. Their
recommendation was that the scientific community
should understand the multiple hypotheses that were a
priori under consideration, in order to understand and in-
terpret the adaptive randomized clinical trial results.
As direct comparative study between more complicated
designs alongside more traditional, simple designs is lack-
ing and mostly limited to simulation studies, respondents
argued the need for more experience with adaptive de-
signs. According to a patient advocate, as experience
grows and ACT designs are used more universally, effi-
ciency in clinical research should improve. Errors and
misunderstandings would be minimized with greater ex-
perience, and the improved reliability of results would re-
sult in great acceptance by clinicians and patients.
The structures and traditions of the clinical trial process
are relevant to the consideration of adaptive design in
the “learning” and “confirming” phases
A clinician trialist noted that phase II trials have typically
been focused and smaller. This trialist noted that many as-
sumptions regarding inclusion population, dose, and dur-
ation of treatment are made and cemented here. He also
noted that the opportunity to make many of these deci-
sions prospectively and quantitatively is lost, and instead
the phase III design may be informed by underpowered
subgroup analyses from these smaller trials.
As a clinician trialist pointed out, phase II trials using
adaptive designs may be larger than phase II trials in the
past; however, this enables a smaller, more focused phase
III study with better controls for type I and type II er-
rors. This trialist noted that the idea of inversion (larger
phase II and smaller phase III trials) would run counter
to long traditions at NIH and in academia.
An academic biostatistician had detailed thoughts re-
garding the current atmosphere of clinical trials and how
decisions to proceed from phase II to III are conducted.
I hope the NIH, in particular, will adopt phase II
strategies that use adaptive design strategies to better
control the type I and type II errors as treatment
investigations proceed from phase II to phase III. As a
general rule, the setting and conditions under which
phase III studies are conducted do not exactly mirror
those of the antecedent phase II studies, in part due to
a certain amount of “data-dredging” of the phase II
data…..Were the NIH to take a more systematic
approach to evaluating the phase II to phase III
transition, the prevalence of “negative” phase III
studies could be greatly decreased.
Discussion
The respondents had varying opinions regarding
adaptive trials
We observed diverse opinions regarding ACT designs.
We provided no definition of adaptive designs or fram-
ing to the participants prior to their completing the VAS
surveys other than that this was an FDA/NIH project on
adaptive designs for confirmatory trials. Most responses
to VAS surveys were in a neutral range; however, some
differences across constituency were observed. Partici-
pants generally believed that clinicians in practice will
have the most difficulty understanding ACT designs,
whereas the FDA will understand such designs relative
to regulatory approval. This suggests the need for
greater education of the broader community regarding
ACT designs. Responses from study section members
were more varied. Overall the study section respondents
indicated that they believed NIH review panels would be
able to understand phase II and III trials and be able to
accept phase II trials more than phase III trials. Interest-
ingly, study sections seemed to have a lower opinion
regarding the potential for ACTs to improve patient care
faster than traditional trials.
Important implications of this work for each constituency
studied
The current investigation has several important implica-
tions for the various constituencies we studied. We con-
sider the academic paradigm of clinicians conceiving of
a trial design, collaborating with biostatisticians to refine
the scientific experiment, submitting to the NIH for a
funding decision (with peer review by clinicians and
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biostatisticians), and regulators (FDA) making decisions
about approving treatments for use. For clinicians, the
implications of our observations are clear: Better under-
standing is needed so that current enthusiasm for adap-
tive designs can be harnessed in a scientifically useful
way. An important further area of work is improved
insight that allows clinicians to understand when adding
complexity can be helpful and worth the cost. The most
important implications for biostatisticians involve com-
munication, both among themselves and to the clinical
audiences. Our findings are distinct from the industry-
focused surveys of the Adaptive Designs working group,
where it seems that communication is perceived as a
lessening barrier [11]. Adaptive designs require more up-
front planning, and the communication of simulations is
quite difficult, even with an in-person meeting. The
communication of a complicated design within a short
grant application is a big challenge. Our work’s import-
ant implication for funders also stems from these com-
munication and development issues: Mechanisms should
be put into place to allow for the careful simulation and
description of designs before funding, and possibly even
for “design competitions” prior to submitting full trial
proposals. This clearly would introduce major challenges
(reference scenarios to simulate), but given the current
low success rate for phase III clinical trials, it is a change
that would likely accelerate scientific discovery [24–27].
In addition, a rethinking of the “small” learning phase II
trial (where little is learned) and the larger phase III trial
(where assumptions made on limited data from the
smaller phase II trial are enforced as fixed trial charac-
teristics) may be worthwhile for governmental funders
to consider [28, 29]. Finally, the implications for regula-
tory bodies of this work are interesting. In general, regu-
latory agencies are deemed to have the most experience
and scientific knowledge of the performance of these de-
signs, although they are frequently believed to be conser-
vative. Methods to capitalize on this expertise (serving
on NIH review panels and helping to set up “design
competitions”) across governmental trial development
initiatives should actively be sought.
Scientific dissatisfaction with the current clinical trial
development pathway is common
The qualitative analysis provided important insights into
the domains of acceptability, understandability, validity,
and the potential efficiency of ACT designs. In addition,
several responses addressed an important limitation in
the current trial development process within the NIH:
Phase II trials typically do not lend themselves to quanti-
tative decision making regarding the most promising
agents, treatment regimens, and populations to investi-
gate further in phase III trials. Clinician trialists, aca-
demic biostatisticians, consultant biostatisticians, and
others highlighted this major current limitation in the
traditional approach to clinical trials and perceived
major barriers in many constituencies to “inverting” the
discovery progress to have larger, more informative
phase II trials, followed by more focused and likely
smaller phase III trials. The current approach, which in-
volves a currently high prevalence of phase III trials
whose results do not well inform clinical practice, was
described unfavorably. One respondent related that the
“data-dredging” that often goes on between phase II and
III is contributing to failure by the pursuit of false sig-
nals, and that a more coordinated, quantitative approach
with pre-specified decision rules could improve the im-
pact of phase III trials.
Adaptive designs have more to offer than reduced
sample sizes, yet it is difficult to quantify the benefit of
flexibility
Next, an important area of response is the potential effi-
ciency gained from the incorporation of adaptive de-
signs. Many of the clinician trialists participating had
little background with adaptive trials at the time of data
collection. As such, the prevailing opinion was that
adaptive designs offer great promise because they can re-
duce sample size and thus the cost of the study. Some
clinicians did have some experience and had unique in-
sights. One response in particular, regarding the tradeoff
between learning about the efficacy of several AEDs ver-
sus more precision in learning about the side effects of
the agents with precision, was telling. Regardless of ul-
timate design decisions for adaptive versus more trad-
itional designs, open discussion of the value of the
diverse sets of clinical data collected during a trial is
clearly important. With respect to efficiency, biostatisti-
cians and regulatory scientists had a broader view. While
it is possible to reduce sample size, answer more ques-
tions, or terminate trials of non-efficacious treatments
sooner in many cases, great care must be taken to en-
sure that good scientific principles are followed in ex-
perimental design. Some previous adaptive designs that
these constituents have experienced may have been less
rigorous; therefore, many responses discussed the great
diversity in what sorts of designs are truly adaptive.
A lack of a common language inhibits the uptake and use
of adaptive trials
Building upon the diversity of clinical trials considered
adaptive, the definition of an ACT was elusive and var-
ied among the constituents in this baseline mixed
methods study. Many of the consultant statisticians who
had designed and conducted a large number of trials felt
that the pre-specification and simulation of the entire
design was implied in the term: adaptive clinical trial.
On the other hand, academic biostatisticians, clinician
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trialists, and study section members had a less specific
view and broadly considered the terminology to include
trials with ad hoc changes based on accumulating data
and relatively well-established group sequential designs.
As a result, in many responses these groups were de-
scribing different types of adaptive designs. It was
pointed out that “adaptive clinical trials” have become
desirable, and that the term has become a buzzword of
sorts. Other work has previously attempted to provide a
taxonomy for describing adaptive designs [30], and the
FDA has provided guidance on “generally well-
understood” adaptive designs and also classified some
types of designs as needing further research and valid-
ation [3]. Overall, this lack of an intuitive common lan-
guage represents a large current barrier as clinicians and
biostatisticians work to design clinical trials. In addition,
the scientific community needs specific efforts to im-
prove the communication of these designs both among
biostatisticians and to clinical audiences. Our work,
which focused on interviewing principal investigators and
statisticians developing clinical trial designs within the
ADAPT-IT project, reinforced the need for more educa-
tion and collaboration in academic trial development,
particularly for more complicated adaptive designs.
Limitations
This study has several important limitations. First, this
was a relatively small study — however, key decision
makers and clinical trialists were approached. The current
study elicited opinions regarding the performance of ACT
designs in various settings (NIH and FDA review, trial op-
eration, knowledge translation), and these opinions may
not reflect the reality regarding the response to ACTs in
the broader biomedical community. While the ADAPT-IT
project involved education, collaboration, and a shared de-
sign process among stakeholders from academia, industry,
and government, this cross-sectional study occurred prior
to any of the participants engaging in these activities to-
gether. It is likely that opinions, knowledge, and attitudes
have changed after participating in ADAPT-IT project ac-
tivities. Finally, we did not define ACTs for the partici-
pants prior to their completion of the VAS or interviews.
Certain individuals with some experience with adaptive
designs (particularly biostatisticians) may have felt unable
to respond outside the neutral range without knowing
what sort of adaptive designs the questions were referen-
cing. This may be explained by a general ambivalence to
adaptive designs within our stakeholders or by the great
diversity of clinical trials that can be described as adaptive.
In retrospect, our results may have changed if some add-
itional information regarding the types of adaptive designs
for which we wanted opinions were more explicitly stated.
On the other hand, given that each individual brought his
or her own internal definition to the table, we were able to
collect rich textual comments that describe some of the
potential benefits and drawbacks of several approaches.
Conclusions
In summary, we found highly diverse opinions about
the utility, efficiency, and stakeholder-specific under-
standing and acceptance of adaptive clinical trials.
First and foremost, the definition of adaptive clinical
trial varied across groups — when working in this area
it is important to ensure that the types of adaptations
under discussion are well described and understood.
Next, clinician and non-statistician researcher under-
standing in this area is limited, and additional educa-
tion and experience with the conduct and
dissemination of adaptive designs seems the most im-
portant way to improve this. Similarly, statisticians
have varied experience with adaptations. Nearly all
biostatisticians involved with clinical trials have ex-
perience with group sequential designs, which could
be considered the best-understood type of adaptive
design. Far fewer have much experience with newer,
more flexible and innovative types of adaptations. Im-
portant barriers to acceptance were identified, espe-
cially variable knowledge and potential misperceptions
regarding how more innovative designs will fare in
peer review. Many of the discussions highlight the
problem with the structure of progression from phase
II to III, an area that is widely recognized to be per-
forming poorly in identifying treatments that prove to
be successful in confirmatory trials. Since the phase II
to III transition is generally not conducted according
to pre-defined rules and data, this represents a poten-
tial area for improvement: namely, by conducting
phase II trials that are better at selecting agents, doses,
treatment regimens, and populations and facilitating
objective, quantitative decision making about the
structure of phase III trials. Finally, given the diversity
of clinical trial designs considered adaptive, it is cru-
cially important that the fundamentals of a sound sci-
entific approach and progression be considered from
the start of trial planning.
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